| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 12/11/2008 | 15:00 | PR Newswire (US) | Deloitte Names Abraxis BioScience Inc. Fastest Growing Technology Company in Los Angeles Area | NASDAQ:ABBI | Abraxis Bioscience (MM) |
| 12/11/2008 | 14:00 | PR Newswire (US) | Deloitte Unveils 2008 Technology Fast 500 Ranking | NASDAQ:ABBI | Abraxis Bioscience (MM) |
| 13/11/2007 | 23:02 | Edgar (US Regulatory) | Abraxis Bioscience, Inc. (Other) (S-8 POS) | NASDAQ:ABBI | Abraxis Bioscience (MM) |
| 13/11/2007 | 22:55 | Edgar (US Regulatory) | Abraxis Bioscience, Inc. (Other) (POSASR) | NASDAQ:ABBI | Abraxis Bioscience (MM) |
| 13/11/2007 | 17:19 | Edgar (US Regulatory) | Abraxis Bioscience, Inc. (Other) (8-K) | NASDAQ:ABBI | Abraxis Bioscience (MM) |
| 08/11/2007 | 17:03 | Edgar (US Regulatory) | Abraxis Bioscience, Inc. - Current report filing (8-K) | NASDAQ:ABBI | Abraxis Bioscience (MM) |
| 05/11/2007 | 22:58 | Edgar (US Regulatory) | Abraxis Bioscience, Inc. - Prospectus filed pursuant to Rule 424(b)(7) (424B7) | NASDAQ:ABBI | Abraxis Bioscience (MM) |
| 30/10/2007 | 21:23 | Edgar (US Regulatory) | Abraxis Bioscience, Inc. - Statement of Changes in Beneficial Ownership (4) | NASDAQ:ABBI | Abraxis Bioscience (MM) |
| 30/10/2007 | 21:22 | Edgar (US Regulatory) | Abraxis Bioscience, Inc. - Amended Statement of Changes in Beneficial Ownership (4/A) | NASDAQ:ABBI | Abraxis Bioscience (MM) |
| 10/08/2007 | 14:05 | Business Wire | APP Receives Expedited Approval for the First and Only Generic Cefotetan Disodium for Injection | NASDAQ:ABBI | Abraxis Bioscience (MM) |
| 10/08/2007 | 02:50 | Business Wire | Abraxis BioScience Files Information Statement in Connection with Its Announced Separation into Two Publicly Traded Companies | NASDAQ:ABBI | Abraxis Bioscience (MM) |
| 09/08/2007 | 14:05 | Business Wire | Abraxis BioScience Reports Second Quarter 2007 Revenue of $243 Million versus $161 Million in Prior Year Period | NASDAQ:ABBI | Abraxis Bioscience (MM) |
| 09/08/2007 | 04:35 | Business Wire | Abraxis BioScience Announces Licensing Agreement with Biocon Limited for the Commercialization of ABRAXANE in India | NASDAQ:ABBI | Abraxis Bioscience (MM) |
| 09/08/2007 | 00:20 | Business Wire | Abraxis BioScience Launches Doxorubicin Hydrochloride Injection, USP | NASDAQ:ABBI | Abraxis Bioscience (MM) |
| 07/08/2007 | 14:00 | Business Wire | Abraxis BioScience Receives FDA Approval for Oxytocin Injection 10 USP Units/mL in a 30 mL Vial | NASDAQ:ABBI | Abraxis Bioscience (MM) |
| 06/08/2007 | 22:15 | Business Wire | Abraxis BioScience Receives Final Approval for Fosphenytoin Sodium Injection, USP | NASDAQ:ABBI | Abraxis Bioscience (MM) |
| 06/08/2007 | 14:00 | Business Wire | Abraxis BioScience Acquires from the Buck Institute Exclusive Worldwide Intellectual Property Rights for Technologies Designed t | NASDAQ:ABBI | Abraxis Bioscience (MM) |
| 03/08/2007 | 00:55 | Business Wire | Abraxis BioScience Receives FDA Approval for Caffeine Citrate Injection USP, 20 mg/mL | NASDAQ:ABBI | Abraxis Bioscience (MM) |
| 31/07/2007 | 22:45 | Business Wire | Abraxis BioScience Acquires Manufacturing Facility from Watson | NASDAQ:ABBI | Abraxis Bioscience (MM) |
| 26/07/2007 | 14:00 | Business Wire | Abraxis BioScience and the California NanoSystems Institute Announce Partnership for Collaborative Research in the Development o | NASDAQ:ABBI | Abraxis Bioscience (MM) |
| 19/07/2007 | 22:05 | Business Wire | Abraxis BioScience and Biocon Limited Announce Licensing Agreement for G-CSF in North America and the European Union | NASDAQ:ABBI | Abraxis Bioscience (MM) |
| 16/07/2007 | 22:05 | Business Wire | Abraxis BioScience Announces Date for Second Quarter Financial Results and Investor Conference Call | NASDAQ:ABBI | Abraxis Bioscience (MM) |
| 02/07/2007 | 13:05 | Business Wire | Abraxis BioScience Announces Plan to Separate Into Two Independent Public Companies | NASDAQ:ABBI | Abraxis Bioscience (MM) |
| 19/06/2007 | 14:00 | Business Wire | Abraxis BioScience Exclusively Licenses Intellectual Property Portfolio Designed to Personalize Treatment for Colorectal Cancer | NASDAQ:ABBI | Abraxis Bioscience (MM) |
| 07/06/2007 | 14:00 | Business Wire | Abraxis BioScience to Present at the Goldman Sachs 28th Annual Global Healthcare Conference | NASDAQ:ABBI | Abraxis Bioscience (MM) |
| 05/06/2007 | 03:33 | PR Newswire (US) | New Data Shows Promising Antitumor Activity with nab-paclitaxel (ABRAXANE(R)) in Combination and as a Single Agent for the Treat | NASDAQ:ABBI | Abraxis Bioscience (MM) |
| 02/06/2007 | 15:05 | Business Wire | ABRAXANE Demonstrates Longer Progression-Free Survival versus Taxotere in the Treatment of First-Line Metastatic Breast Cancer | NASDAQ:ABBI | Abraxis Bioscience (MM) |
| 30/05/2007 | 14:05 | Business Wire | New Data Highlighting ABRAXANE as Single Agent and in Combination for the Treatment of Breast, Lung and Ovarian Cancers to Be Pr | NASDAQ:ABBI | Abraxis Bioscience (MM) |
| 23/05/2007 | 14:00 | Business Wire | Abraxis BioScience to Present at the Bank of America 2007 Health Care Conference | NASDAQ:ABBI | Abraxis Bioscience (MM) |
| 14/05/2007 | 22:05 | Business Wire | Abraxis BioScience Founder Awarded Ellis Island Medal of Honor | NASDAQ:ABBI | Abraxis Bioscience (MM) |